CooperVision advocates myopia control and management at ESCRS Congress
The fourth congress of the European Society of Cataract and Refractive Surgeons (ESCR) took place at the Messe Wien Exhibition & Congress Center from September 8 to 12. Based in London, the ESCRS has been promoting international networking in the field of ophthalmology since 1991 and has over 7,500 members from 130 countries.
CooperVision was also present at this major annual event, which was attended by thousands of ophthalmologists, researchers and educators, and took center stage at various discussion rounds and leadership panels on the topic of myopia control and myopia management.
CooperVision thus underlined its leading role worldwide. The company was already active on September 7 in the run-up to the major congress at a leadership panel of the "Ophthalmology Futures Forum", which was moderated by Marcus Ang. At the Hilton Vienna Danube Waterfront, Elizabeth Lumb* debated the topic "Myopia in the digital age.
On September 8, the "World Society of Paediatric Ophthalmology and Strabismus' (WSPOS) Subspecialty Day", sponsored by CooperVision, continued. Elizabeth Lumb chaired the panel "Management and control; The Value of Optical Intervention in Myopia Control". Speakers included Ian Flitcroft, whose clinical research and entrepreneurial activities are recognized worldwide. He spoke about his latest research on the efficacy of low-dose atropine, myopia control in Western versus Asian populations and models of collaboration between ophthalmology and optometry. "The global scale of the myopia problem and the availability of both optical and pharmacological care means that this is not a question of ophthalmology or optometry, but a question of collaboration and partnership," Flitcroft said of his vision for the future of myopia care.
"Our partnership with the ophthalmic community through initiatives like the ESCRS underscores CooperVision's unwavering commitment to advancing eye health through evidence-based approaches to myopia management," says Lumb. "Ophthalmology plays an essential role in driving innovation, generating evidence and advancing the future of myopia control and management. And we are proud to support here."
CooperVision's MiSight 1 day is the first and only soft contact lens approved by the US FDA and China NMPA for slowing the progression of myopia in children aged 8 to 12 years at the start of care. CooperVision also offers a range of orthokeratology designs and eyewear with Diffusion Optics Technology for myopia management.
More information on the "Opthalmology Futures Forum" can be found at www.ophthalmology-futures.com.
* BSc (Hons) MCOptom, FBCLA, Director of Global Professional Affairs, Myopia Management CooperVision
